What the cardiovascular trials actually measured for tirzepatide, which heart markers may change, and how to bring heart health into your next appointment.

If you live with type 2 diabetes or obesity, you probably check the scale more than anything else. That makes sense. But Mounjaro heart health depends on much more than your weight. This article goes deeper than the overview we shared earlier on MounjaBlog. We'll look at what the cardiovascular trials measured, what they did not prove, and how to bring these questions to your doctor.

Why the scale is only part of the heart story

Cardiovascular risk comes from several factors at once. The American Heart Association lists high blood pressure, high cholesterol, high blood sugar, smoking, and physical inactivity among the main ones, and kidney health matters too. A medication can influence some of these factors, but it can't replace the rest of your heart care plan.

That leads to the question many people ask: if I lose weight, is my heart automatically safer? Weight loss often improves several risk factors together, but it doesn't guarantee a safer heart by itself. Blood pressure, cholesterol, and blood sugar each still need their own attention.

What the big cardiovascular trial actually tested

Doctor takes elderly patient's blood pressure

SURPASS-CVOT is the study most people mean. Researchers compared tirzepatide with dulaglutide, another weekly diabetes medicine, in adults with type 2 diabetes who already had cardiovascular disease or were at high risk. Because both groups received an active drug, the comparison answered a different question than a trial against placebo would. The results were published in the New England Journal of Medicine in 2025, and the trial is registered as NCT04255433 on ClinicalTrials.gov.

The primary endpoint was MACE, short for major adverse cardiovascular events. It typically combines cardiovascular death, heart attack, and stroke into one measure. Researchers use a combined endpoint because each event is serious but fairly uncommon. Grouping them gives a clearer signal than tracking each one alone.

Two terms matter here. Noninferiority asks whether a treatment is not worse than the comparison. Superiority asks whether it is actually better. SURPASS-CVOT was designed to test noninferiority first. Tirzepatide met that bar on the primary endpoint, so it was not worse than dulaglutide. That result does not show it was better. When a headline claims a drug protects the heart more, check which question the trial answered.

Also remember that results describe the people who were studied. Labels can differ by country, so what applies in one place may not match the approved use where you live.

Heart-related markers that may change

Blood pressure is often the first marker people notice. Some users see their numbers drop, and weight loss in general can help. Others see little change. Home readings are useful because a single clinic measurement can be affected by stress and timing. The AHA recommends sitting quietly for a few minutes, using the same arm, and measuring at a consistent time of day.

Blood fats can shift too. Better weight and glucose control may influence triglycerides and cholesterol. That's why a lipid panel belongs in your baseline and follow-up tests. Your doctor may adjust cholesterol treatment based on those results, not on the injection alone.

HbA1c reflects your average blood sugar over roughly three months. Better long-term control is linked to healthier blood vessels over time, so track this number with your team. No specific outcome is guaranteed, though.

Heart rate deserves its own attention. A faster resting heart rate is a known effect in some people taking tirzepatide, and the prescribing information describes it. The AHA gives a typical resting range of 60 to 100 beats per minute for adults. If your pulse stays above that range or you notice palpitations, share your readings with your doctor instead of waiting for the next visit.

Where the evidence is still growing

Some of the most interesting research looks at heart failure with preserved ejection fraction (HFpEF) in people with obesity. In this condition, the heart pumps normally but stiffens and struggles to fill properly. That can cause breathlessness and limit daily activity. The SUMMIT trial (NCT04847557) tested tirzepatide in people with HFpEF and obesity, and its published report described improvements in symptoms and physical function. Read the primary and secondary endpoints yourself to see exactly what was measured.

Larger outcome trials in people with obesity but without diabetes are still running, including SURMOUNT-MMO (NCT04844918). These studies aim to show whether tirzepatide reduces serious cardiovascular events in that group. Results aren't available yet, so heart benefits for this group should be treated as promising, not settled. The registry lists the current status and expected completion.

A benefit seen in a trial doesn't automatically become an approved indication. Approved uses vary by country, so check the label for your region with your doctor or in ANVISA's bulário, Brazil's drug label database.

Safety points that connect to heart care

Your heart and kidneys work closely together. Nausea, vomiting, or eating and drinking much less can leave you dehydrated. That can lower blood pressure and strain the kidneys. The Mounjaro label warns about kidney problems linked to dehydration from gastrointestinal side effects. If you feel lightheaded when you stand up or you aren't drinking enough, tell your team early.

Blood pressure medicines and diuretics may need a review if your readings drop after you start tirzepatide. Don't stop them on your own. Your team can decide whether a dose should change.

Insulin and sulfonylureas raise the risk of low blood sugar when combined with tirzepatide. The label describes this risk. The Brazilian Diabetes Society (Sociedade Brasileira de Diabetes, SBD) lists hypoglycemia symptoms such as shakiness, sweating, confusion, and a racing heart. Those overlap with palpitations and dizziness, so report them promptly. Your doctor may lower those doses, but never change them yourself.

Medicine interactions need careful attention. Statins, antiplatelet drugs, and other heart medicines should stay in place unless a doctor changes them. List everything you take, including supplements and over-the-counter pills, and share that list with your team. MounjaBlog's guides on side effects are a good starting point for reading, but they don't replace advice from the people treating you.

How to talk about heart health with your care team

Before you start, ask for a baseline review. Most teams check blood pressure, a lipid panel, kidney function through creatinine and eGFR, and HbA1c. An ECG may be recommended if a cardiologist thinks it's needed. Having these results on file makes changes easier to spot later.

Next, start a simple home log. Record blood pressure, resting heart rate, weight, and any dizziness, nausea, or changes in how much you drink. Note the date and time, keep it in a notebook or a phone app, and bring it to every visit. Writing things down beats trying to remember numbers from last month. Bringing that written record to each visit, which is the habit we recommend at MounjaBlog, keeps the conversation focused on what matters.

Then ask specific questions. Am I at high cardiovascular risk? Which of my heart medicines should I keep? What numbers should trigger a call? Write the answers down so you can review them later.

Realistic expectations and when to seek urgent care

In short, tirzepatide may support heart health through several pathways, including weight, blood sugar, and possibly blood pressure and blood fats. It doesn't replace blood pressure control, cholesterol management, smoking cessation, or regular follow-up. Treat it as one part of the plan.

Some symptoms can't wait for a scheduled visit. Call emergency services right away if you notice any of these:

Chest pain or pressure that doesn't ease
Sudden shortness of breath or fainting
A racing or irregular heartbeat that doesn't settle

In Brazil, dial SAMU at 192, the Ministry of Health's emergency medical service. Headaches, nausea, and other common side effects have their own posts, so check those if they bother you.

Bring these questions to your next appointment and let your doctor tailor the plan to your history and numbers. Any change to your heart medicines should come from that conversation, not from this article.

FAQ

Does Mounjaro protect the heart?

It may help some cardiovascular risk factors, such as weight, blood sugar, and in some people blood pressure. The main trial showed tirzepatide was not worse than dulaglutide for major heart events, but it did not clearly prove it is better. Ask your doctor how it fits your personal risk.

Can tirzepatide raise my heart rate?

A faster resting heart rate is a known effect for some people. Track it at home, and contact your doctor if it stays above the typical range or you feel palpitations.

Should I stop my statin or blood pressure pill when I start?

No, not without talking to your doctor. Heart medicines usually stay in place unless your team changes them, especially if your blood pressure drops after you start treatment.

What is SURPASS-CVOT?

It is a head-to-head trial comparing tirzepatide with dulaglutide in adults with type 2 diabetes and established cardiovascular disease or high risk. Its main question was whether tirzepatide is not worse for major cardiovascular events.

Sources